Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Update

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) was the target of a large decline in short interest during the month of January. As of January 31st, there was short interest totalling 500 shares, a decline of 97.2% from the January 15th total of 18,000 shares. Based on an average daily trading volume, of 485,900 shares, the days-to-cover ratio is currently 0.0 days.

Provectus Biopharmaceuticals Stock Performance

Shares of PVCT traded up $0.00 during mid-day trading on Wednesday, hitting $0.10. 146,001 shares of the company’s stock were exchanged, compared to its average volume of 211,239. Provectus Biopharmaceuticals has a twelve month low of $0.04 and a twelve month high of $0.22. The firm has a fifty day moving average of $0.12 and a two-hundred day moving average of $0.11.

Provectus Biopharmaceuticals Company Profile

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.